FoundationOne®

What is FoundationOne? What?
How does FoundationOne work? How?
Why use FoundationOne? Why?

FoundationOne is a solid tumour profiling service that detects clinically relevant changes (genomic alterations) in cancer-related genes and helps to identify suitable therapies for a patient’s disease,^1–3 by associating each alteration with the latest clinical and scientific evidence.^4,5

FoundationOne can help to identify potentially effective targeted therapies, immunotherapies and investigational therapies for patients, driven by the knowledge of over 100 world-class experts.⁶ This information is presented in a curated, quality-controlled patient report explaining the biological relevance of each alteration in order to assist clinical decision-making.⁵

FoundationOne identifies clinically relevant genomic alterations in the majority of patients, potentially helping to expand treatment options for patients with metastatic or recurrent solid tumour cancer.⁷

Match alterations to potentially beneficial therapies and clinical trials^1,3

The FoundationOne report is fully annotated and comprehensive⁵

FoundationOne has been used to profile over 150,000 patients⁸

References

FoundationOne technical information.
Drilon A et al. Clin Cancer Res 2015; 16:3631–3639.
Rozenblum AB et al. J Thorac Oncol 2017; 2:258–268 (and supplementary material).
Roche Foundation Medicine data on file: Internal presentation. Lab processes: deep dive.
Roche Foundation Medicine Internal Information.
Roche Foundation Medicine data on file: Strategy internal presentation.
Schwaederle M et al. Mol Cancer Ther 2015; 14:1488–1494.
Genomeweb. Foundation Medicine Q3 revenues up 45 percent. Available at: https://www.genomeweb.com/molecular-diagnostics/foundation-medicine-q3-revenues-45-percent [accessed November 2017].

FOUNDATIONONE^®